TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26338885

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol supplements of 10 μg/d for 3 mo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol supplements of 25 μg/d for 3 mo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol supplements of 50 μg/d for 3 mo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 24
Study: 23648394

Group type: EXPERIMENTAL
Intervention: Weight management program 1
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Weight management program 2
Number of subjects: 550

Group type: COMPARATOR
Intervention: Non-randomized observational control group
Number of subjects: 550
Study: 21169285

Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Volume Doubling Time (VDT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Combination of PET and VDT
Number of subjects: 54
Study: 19585872

Group type: EXPERIMENTAL
Intervention: Ecopass traffic restriction fee enforcement
Number of subjects: 0
Study: 17518162

Group type: EXPERIMENTAL
Intervention: Educational intervention (one 60-90 minute session delivered by a nurse and psychologist)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 22
Study: 16513899

Group type: EXPERIMENTAL
Intervention: Academic detailing intervention (multicomponent physician-directed education using American Cancer Society guidelines)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 168
Study: 14597945

Group type: EXPERIMENTAL
Intervention: Balloon-expandable Palmaz stents
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Self-expandable nitinol aortic stents
Number of subjects: 21
Study: 10474084

Group type: EXPERIMENTAL
Intervention: Blood transfusion (average 4.49+/‐3.3 U/patient, range 1‐14)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Transfusion-associated hepatitis due to HCV
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Transfusion-associated hepatitis due to HBV
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Coinfection of HBV and HCV
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: TAH due to HBV
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: TAH due to HCV
Number of subjects: 182
Study: 8953681

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g b.i.d. for 6 days
Number of subjects: 342

Group type: COMPARATOR
Intervention: Penicillin V 1 MU t.i.d. for 10 days
Number of subjects: 342
Study: 1789034

Group type: EXPERIMENTAL
Intervention: Lyophilized acellular staphylococcal vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 0
Study: 7019230

Group type: EXPERIMENTAL
Intervention: salmon calcitonin (100 Medical Research Council Units)
Number of subjects: 16
Study: 29995274

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) over the medial frontal cortex (MFC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 16
Study: 28936901

Group type: EXPERIMENTAL
Intervention: Inductive learning approach
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Deductive learning approach
Number of subjects: 84
Study: 26220050

Group type: EXPERIMENTAL
Intervention: Exercise Training plus Phototherapy (ET-PHOTO)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Exercise Training plus SHAM (ET-SHAM)
Number of subjects: 64
Study: 23864540

Group type: EXPERIMENTAL
Intervention: Oral thiamine hydrochloride 100 mg for 5 days
Number of subjects: 16
Study: 20939638

Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 379
Study: 18244953

Group type: EXPERIMENTAL
Intervention: TPI ASM8 (1,500 microg, inhaled by nebulizer, once daily for 4 days)
Number of subjects: 17
Study: 15697326

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5mg nasal spray
Number of subjects: 2122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2122
Study: 12591752

Group type: EXPERIMENTAL
Intervention: Mitral valve (MV) repair surgery
Number of subjects: 26
Study: 10932687

Group type: EXPERIMENTAL
Intervention: 1.5 mg.kg‐1 propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2.5 mg.kg‐1 propofol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Low dose propofol (1.5 mg.kg‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High dose propofol (2.5 mg.kg‐1)
Number of subjects: 80
Study: 8671971

Group type: EXPERIMENTAL
Intervention: CU dialyser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CTA dialyser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PS dialyser
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CTA, CU, and PS dialysers
Number of subjects: 8
Study: 1768565

Group type: EXPERIMENTAL
Intervention: Atenolol (1 x 100 mg day‐1) for 6 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Captopril (1 x 100 mg day‐1) for 6 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atenolol and Captopril
Number of subjects: 16
Study: 6817776

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 20 mg q.d.s.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketotifen 1 mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31927027

Group type: EXPERIMENTAL
Intervention: TCu380A IUD
Number of subjects: 140

Group type: COMPARATOR
Intervention: Levonorgestrel (LNG) 52 mg IUS
Number of subjects: 140
Study: 31796495

Group type: EXPERIMENTAL
Intervention: PEEK cranioplasty
Number of subjects: 140

Group type: COMPARATOR
Intervention: Titanium cranioplasty
Number of subjects: 140
Study: 28439700

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pegfilgrastim
Number of subjects: 42
Study: 26369653

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 20
Study: 23904883

Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate (CC) + Metformin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clomiphene Citrate (CC) alone
Number of subjects: 42
Study: 21338805

Group type: EXPERIMENTAL
Intervention: High-milk, early-weaned: fed 12 L/d of milk and weaned at 47 d of age
Number of subjects: 9

Group type: COMPARATOR
Intervention: Low-milk, early-weaned: fed 6 L/d of milk and weaned at 47 d of age
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High-milk, later-weaned: fed 12 L/d of milk and weaned at 89 d of age
Number of subjects: 9
Study: 19270249

Group type: EXPERIMENTAL
Intervention: Scales of Psychological Capacities (SPC) applied to borderline patients
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Scales of Psychological Capacities (SPC) applied to depressed women
Number of subjects: 105

Group type: COMPARATOR
Intervention: Scales of Psychological Capacities (SPC) applied to healthy controls
Number of subjects: 105
Study: 17418321

Group type: EXPERIMENTAL
Intervention: Hygiene promotion (medicine provided and hygiene promotion activity)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Treatment (medicine provided, no hygiene promotion activity)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Seasonality (no medicine, no hygiene promotion activity)
Number of subjects: 276
Study: 15478381

Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11402366

Group type: EXPERIMENTAL
Intervention: SCIM
Number of subjects: 22

Group type: COMPARATOR
Intervention: FIM
Number of subjects: 22
Study: 9430868

Group type: EXPERIMENTAL
Intervention: Single-cuff Tenckhoff catheter
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double-cuff Tenckhoff catheter
Number of subjects: 60
Study: 8500867

Group type: EXPERIMENTAL
Intervention: 200 mg indomethacin for 5 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 35
Study: 3551668

Group type: EXPERIMENTAL
Intervention: EFA supplementation
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30789808

Group type: EXPERIMENTAL
Intervention: Resveratrol 600 mg daily for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30513768

Group type: EXPERIMENTAL
Intervention: Hypocaloric very low carbohydrate (VLC) diet (4⁻10% of total energy intake)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hypocaloric low fat (LF) diet (<30% of total energy intake)
Number of subjects: 36
Study: 27091274

Group type: EXPERIMENTAL
Intervention: Heel suspension device boot
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 183
Study: 24689967

Group type: EXPERIMENTAL
Intervention: Fish oil capsules (4 g daily for 6 weeks)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (identical-looking capsules for 6 weeks)
Number of subjects: 21
Study: 22945713

Group type: COMPARATOR
Intervention: Variolink II (Var II) resin cement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maxcem (Mc)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multilink Sprint (MS)
Number of subjects: 40
Study: 20156150

Group type: EXPERIMENTAL
Intervention: Galantamine (8-32 mg for IR tablets; 8-24 mg for ER capsules)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine co-administered with ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine co-administered with paroxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine in patients with moderate renal impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine in patients with severe renal impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galantamine in patients with moderate hepatic impairment
Number of subjects: 0
Study: 18294323

Group type: EXPERIMENTAL
Intervention: Ifosfamide 9 g m(‐2) given by a 3 h infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ifosfamide 9 g m(‐2) given by a 72 h infusion
Number of subjects: 17
Study: 16187510

Group type: EXPERIMENTAL
Intervention: Participants with PFPS after sitting for 20 minutes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Participants with PFPS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study: 14516798

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (Group 3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Topical artificial tear substitute (ATS) (Group 1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ATS plus nonsteroidal anti-inflammatory drops (NSAID) (Group 2)
Number of subjects: 32
Study: 11368654

Group type: EXPERIMENTAL
Intervention: 25 g of OSA-substituted starch
Number of subjects: 30

Group type: COMPARATOR
Intervention: 25 g of glucose
Number of subjects: 30
Study: 9196520

Group type: EXPERIMENTAL
Intervention: Adjustable mandibular positioner (AMP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 20
Study: 1494114

Group type: EXPERIMENTAL
Intervention: XR-Ionomer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fuji Lining LC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemically cured glass ionomer cement
Number of subjects: 0
Study: 3516077

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 31504699

Group type: EXPERIMENTAL
Intervention: Whole-Grain (WG) diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Refined-Wheat (RW) diet
Number of subjects: 46
Study: 25416463

Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 496
Study: 26537306

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (three one-hour sessions per week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 23581590

Group type: EXPERIMENTAL
Intervention: Subarachnoid clot burden
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Subdural hematoma
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Subarachnoid clot burden cutoff
Number of subjects: 413
Study: 22139778

Group type: EXPERIMENTAL
Intervention: Web-based simulation followed by manikin simulation (Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Manikin simulation followed by web-based simulation (Group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both simulations
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Manikin simulation
Number of subjects: 40
Study: 19699885

Group type: EXPERIMENTAL
Intervention: CorCap plus RMA
Number of subjects: 30

Group type: COMPARATOR
Intervention: RMA alone
Number of subjects: 30
Study: 16139331

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.8‐4.2)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day plus Warfarin (INR 2.0‐2.5)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: All treatment groups (Aspirin, Warfarin, or both)
Number of subjects: 267
Study: 15632886

Group type: EXPERIMENTAL
Intervention: Direct stenting (DS)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional stenting (CS)
Number of subjects: 128
Study: 11873095

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Pravastatin 20 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 502
Study: 9779038

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 0
Study: 8141163

Group type: EXPERIMENTAL
Intervention: 10 mmol/d Na intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 mmol/d Na intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 400 mmol/d Na intake
Number of subjects: 24
Study: 3207127

Group type: EXPERIMENTAL
Intervention: Oral phenobarbital (90 mg daily)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 52
Study: 1920342

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Labetalol (100-800 mg twice daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 67

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 67
Study: 977134

Group type: EXPERIMENTAL
Intervention: Griseofulvin tablets containing dioctyl sodium sulfosuccinate, cetyl pyridinium chloride and polysorbate 80
Number of subjects: 128

Group type: COMPARATOR
Intervention: Griseofulvin tablets only
Number of subjects: 128
Study: 31965616

Group type: EXPERIMENTAL
Intervention: Detomidine (0.03 mg/kg bwt)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Xylazine (1.1 mg/kg bwt)
Number of subjects: 57
Study: 30642925

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir or efavirenz plus tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 817

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir or efavirenz plus abacavir/lamivudine
Number of subjects: 817
Study: 27732034

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) + Work Therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Work Therapy (Control)
Number of subjects: 48
Study: 26684708

Group type: EXPERIMENTAL
Intervention: Green exercise intervention (outdoors in a green/nature area)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Indoor exercise setting (control group)
Number of subjects: 14
Study: 23121002

Group type: EXPERIMENTAL
Intervention: Psychoeducative group therapy (six sessions during pregnancy and one after childbirth)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Psychoeducative group therapy (n = 90 participants)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Psychoeducative group therapy
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group (care by community nurses and referral if necessary)
Number of subjects: 371
Study: 21637086

Group type: EXPERIMENTAL
Intervention: GI‐NP (n = 50)
Number of subjects: 150

Group type: COMPARATOR
Intervention: GI‐MD (n = 100)
Number of subjects: 150
Study: 19386744

Group type: EXPERIMENTAL
Intervention: Phylloquinone (vitamin K1) supplementation (500 microg/d)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Multivitamin alone (control)
Number of subjects: 388
Study: 16690701

Group type: EXPERIMENTAL
Intervention: Exercise at approximately 67% VO2peak
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Exercise at 35%, 60%, and 85% VO2peak
Number of subjects: 18
Study: 15503108

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 400 mg/d titrated to 1200 mg/d, then maintained or increased to 2400 mg/d or 3600 mg/d if not beneficial
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11687995

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (36 degrees C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypothermic CPB (25 degrees C)
Number of subjects: 20
Study: 9488070

Group type: EXPERIMENTAL
Intervention: HE-TUMT
Number of subjects: 52

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 52
Study: 7996372

Group type: EXPERIMENTAL
Intervention: Electroencephalographic abnormalities (burst suppression or electrographic seizure)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Single recording of electrographic seizure or burst suppression
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation immediately before ECMO
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Lowest systolic blood pressure before or during ECMO
Number of subjects: 119
Study: 2894070

Group type: EXPERIMENTAL
Intervention: Azo compounds (sulphasalazine and olsalazine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Slow-release compounds (Pentasa, Asacol, and Salofalk)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Plain 5-ASA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Azo compounds
Number of subjects: 8

Group type: COMPARATOR
Intervention: Slow-release compounds
Number of subjects: 8
Study: 29664951

Group type: EXPERIMENTAL
Intervention: Conditional follow-up (return only if illness continued)
Number of subjects: 4434

Group type: COMPARATOR
Intervention: Universal follow-up (return regardless of illness resolution)
Number of subjects: 4434

Group type: EXPERIMENTAL
Intervention: Conditional follow-up (caregiver-reported fever lasting ≥3 days)
Number of subjects: 4434

Group type: COMPARATOR
Intervention: Universal follow-up (caregiver-reported fever lasting ≥3 days)
Number of subjects: 4434

Group type: EXPERIMENTAL
Intervention: Conditional follow-up (axillary temperature measurement)
Number of subjects: 4434

Group type: COMPARATOR
Intervention: Universal follow-up (axillary temperature measurement)
Number of subjects: 4434

Group type: EXPERIMENTAL
Intervention: Conditional follow-up (post hoc analysis for malaria, diarrhea, pneumonia, danger signs, hospitalization, or death)
Number of subjects: 4434

Group type: COMPARATOR
Intervention: Universal follow-up (post hoc analysis for malaria, diarrhea, pneumonia, danger signs, hospitalization, or death)
Number of subjects: 4434
Study: 28648148

Group type: EXPERIMENTAL
Intervention: Debt advice provided by the CAB, treatment as usual (TAU), and two debt advice leaflets.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Advice leaflets provided by the general practitioner and TAU only.
Number of subjects: 61
Study: 26286662

Group type: EXPERIMENTAL
Intervention: BoNT‐A
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BITT
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: BoNT‐A + BITT
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study: 23302601

Group type: EXPERIMENTAL
Intervention: CABG (with cardiopulmonary bypass)
Number of subjects: 40

Group type: COMPARATOR
Intervention: OPCAB (without cardiopulmonary bypass)
Number of subjects: 40
Study: 21961486

Group type: EXPERIMENTAL
Intervention: Nebulized procaterol
Number of subjects: 140

Group type: COMPARATOR
Intervention: Nebulized salbutamol
Number of subjects: 140
Study: 18317194

Group type: EXPERIMENTAL
Intervention: ProDisc-L lumbar disc replacement
Number of subjects: 42
Study: 16981402

Group type: EXPERIMENTAL
Intervention: Exposure assessment based on a single job for active workers and longest job for retired or deceased workers; assessed using a job-exposure matrix.
Number of subjects: 147062

Group type: EXPERIMENTAL
Intervention: Exposure to hazardous factors such as dust, silica, PAHs, CO, and heat.
Number of subjects: 147062
Study: 12706031

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 11576573

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Plain saline
Number of subjects: 140
Study: 15321209

Group type: EXPERIMENTAL
Intervention: Early administration of epidural bupivacaine (0.25%) at cervical dilatation <4 cm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Late administration of epidural bupivacaine (0.25%) at cervical dilatation >=4 cm
Number of subjects: 60
Study: 8151722

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exosurf
Number of subjects: 41

Group type: COMPARATOR
Intervention: Survanta vs Exosurf
Number of subjects: 41
Study: 2904373

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.5 micrograms kg‐1 min‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control saline infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 8
Study: 31805247

Group type: EXPERIMENTAL
Intervention: Phonomotor treatment (56-60 hr over 6 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Semantic Feature Analysis (SFA) treatment (56-60 hr over 6 weeks)
Number of subjects: 58
Study: 27836235

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (using a model-predictive control algorithm to direct subcutaneous delivery of rapid-acting insulin analogue without meal-time insulin boluses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional subcutaneous insulin delivery according to local clinical guidelines
Number of subjects: 40